Page 21 - Glass Machinery Plants & Accessories no. 3/2017

businessnews

www .g lassonline.com

GERRESHEIMER Gerresheimer fell 5.9% in
early trading to the bottom
US HEALTHCARE CONFUSION of the German mid-cap
index, which slipped 0.4%.
Revenues at February as sales in North leaving drugmakers “The fact that the
Gerresheimer’s business America slipped. uncertain as to how pricing management currently
division that makes glass “Greater uncertainty with and demand may be sees just the lower end of
bottles and vials for drugs regard to the new U.S. affected. the FY revenue guidance
fell 2.9 percent in its fiscal government triggered Overall, Gerresheimer’s should not come as a
first quarter. a relatively pronounced revenues were down more major negative surprise
German drugs-packaging reticence among a than 5% at EUR 302.8 after the expected slow
firm Gerresheimer said number of large pharma million (USD 323.1 start to the year,” said
its major pharmaceutical customers to place orders,” million) in the quarter, DZ Bank analyst Sven
customers had been more Gerresheimer said in a missing analyst consensus Kuerten, reiterating his
cautious in placing orders statement, adding that of EUR 307 million in a “buy” rating. Gerresheimer
due to uncertainty over the European cosmetic glass Reuters poll. reiterated that adjusted
new US administration’s sales had risen. The group said it expected earnings before interest,
policies, sending its President Donald Trump full-year revenues at the tax, depreciation and
shares lower. Revenues at has promised to increase lower end of its forecast amortisation (EBITDA)
Gerresheimer’s business competition in the range of EUR 1.405 should rise to around EUR
division that makes glass pharmaceutical industry billion to 1.455 billion. 320 million this year from
bottles and vials for drugs without giving details, Analysts on average see EUR 308 million in 2016,
fell 2.9% in its fiscal first while promised healthcare 2017 revenues of EUR after a 6% slide in the first
quarter through the end of reform has been delayed, 1.43 billion. Shares in quarter.